Two new drugs to battle breast cancer have made their way into the Pharmaceutical Benefits Scheme which is a succor for the multitude of sufferers, who can now avail superior treatment notwithstanding the cost of drugs. This is good news as breast cancer carries the ignominy of being the most common cancer befalling women, affecting 14,000 people annually.
The drugs are targeted at post-menopausal women suffering hormone-dependant early breast cancer, who will be in a position to avail the drug from December 1.
Breast Cancer Network Australia CEO Lyn Swinburne explained that the drugs, called as aromatase inhibitors, were consumed by more than 50% of women suffering breast cancer. Ms Swinburne said "It is important these drugs are on the PBS because they offer women choice. Women shouldn't have to worry about the cost; they have enough decisions to make and options to consider without the added worry of how they are going to pay for these things. What we want is the best treatment for the individual woman to ensure she has the best chance of recovery."
National Breast Cancer Centre acting deputy director Dr Alison Evans said, "Their listing on the PBS is wonderful news as it provides additional treatment options for patients with early breast cancer."